NCT05465954 2026-01-12Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent GlioblastomaMayo ClinicPhase 2 Recruiting54 enrolled
NCT04984811 2024-03-05NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLCNeoImmuneTechPhase 2 Active not recruiting83 enrolled
NCT05191784 2023-06-12GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) PatientsGenexine, Inc.Phase 2 Unknown20 enrolled